A detailed history of Alpha Centric Advisors LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 143,898 shares of URGN stock, worth $2.29 Million. This represents 1.5% of its overall portfolio holdings.

Number of Shares
143,898
Previous 155,000 7.16%
Holding current value
$2.29 Million
Previous $2.33 Million 7.18%
% of portfolio
1.5%
Previous 1.82%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

SELL
$13.81 - $19.33 $153,318 - $214,601
-11,102 Reduced 7.16%
143,898 $2.16 Million
Q4 2023

Feb 14, 2024

SELL
$10.87 - $15.93 $108,699 - $159,300
-10,000 Reduced 6.06%
155,000 $2.33 Million
Q3 2023

Nov 13, 2023

BUY
$8.84 - $22.64 $110,500 - $283,000
12,500 Added 8.2%
165,000 $2.31 Million
Q2 2023

Aug 08, 2023

BUY
$8.75 - $14.29 $1.33 Million - $2.18 Million
152,500 New
152,500 $1.58 Million

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $361M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.